Economic analysis of motor neurone disease in Australia | Deloitte Australia | Deloitte Access Economics report, health has been added to your bookmarks.
Economic analysis of motor neurone disease in Australia
Estimating the health, productivity and burden of disease costs
Motor Neurone Disease Australia commissioned Deloitte Access Economics to analyse the economic costs of motor neurone disease to individuals, government, and the broader Australian community.
In this report, commissioned by Motor Neurone Disease Australia, Deloitte Access Economics estimates the total cost of Motor Neurone Disease (MND) to Australia, including health, productivity and other financial costs (“economic costs”) and the burden of disease costs (the loss of healthy life).
MND is a rare, degenerative nervous system condition that affects approximately 1 in 11,434 Australians, or 2,094 Australians in 2015. Approximately 60% are male and 40% are female. Awareness of MND has advanced considerably over the past decade.
The total per person cost of MND was estimated to be $1.13 million in 2015, and the overall cost to Australian society was estimated to be $2.37 billion in 2015. This is comprised of $1.94 billion in burden of disease costs and $430.9 million in economic costs.